P. Roselt

发表

In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat

M. Grégoire, S. Dedeurwaerdere, D. Binns, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Fully automated one-pot radiosynthesis of O-(2-[18F]fluoroethyl)-L-tyrosine on the TracerLab FX(FN) module.

Tim Jackson, P. Roselt, I. Greguric, 2011, Nuclear medicine and biology.

Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

D. Binns, R. Hicks, G. Reischl, 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Improved Detection of Regional Melanoma Metastasis Using 18F-6-Fluoro-N-[2-(Diethylamino)Ethyl] Pyridine-3-Carboxamide, a Melanin-Specific PET Probe, by Perilesional Administration

R. Hicks, O. Neels, P. Roselt, 2011, The Journal of Nuclear Medicine.

High-Contrast PET of Melanoma Using 18F-MEL050, a Selective Probe for Melanin with Predominantly Renal Clearance

R. Hicks, N. Aide, O. Neels, 2010, Journal of Nuclear Medicine.

In Vivo Measurement of Hippocampal GABAA/cBZR Density with [18F]-Flumazenil PET for the Study of Disease Progression in an Animal Model of Temporal Lobe Epilepsy

M. Grégoire, S. Dedeurwaerdere, D. Binns, 2014, PloS one.

Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer

R. Hicks, Kelly Waldeck, O. Neels, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

ORIGINAL ARTICLE: Pilot comparison of 18F‐fluorocholine and 18F‐fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer

T. DeGrado, R. Hicks, P. Roselt, 2010, Journal of medical imaging and radiation oncology.

18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model

G. McArthur, R. Hicks, N. Aide, 2010, The Journal of Nuclear Medicine.

Imaging of hypoxia with 18F‐FAZA PET in patients with locally advanced non‐small cell lung cancer treated with definitive chemoradiotherapy

D. Ball, R. Hicks, D. Rischin, 2013, Journal of medical imaging and radiation oncology.

of Mice Bearing Abdominal Tumors

R. Hicks, N. Aide, C. Cullinane, 2011 .

A Dual Radiologic Contrast Agent Protocol for 18F-FDG and 18F-FLT PET/CT Imaging of Mice Bearing Abdominal Tumors

R. Hicks, N. Aide, C. Cullinane, 2011, Molecular Imaging and Biology.

18 F-Flumazenil : A g-Aminobutyric Acid A – Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy

M. Grégoire, D. Binns, M. Cook, 2013 .

Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.

R. Hicks, O. Neels, P. Roselt, 2009, Journal of medicinal chemistry.

The role of positron emission tomography in the discovery and development of new drugs; As studied in laboratory animals

S. Meikle, M. Kassiou, P. Roselt, 2010, European Journal of Drug Metabolism and Pharmacokinetics.

small animal PET results

D. Binns, R. Hicks, G. Reischl, 2007 .

Synthesis and Radiosynthesis of a Novel PET Fluorobenzyl Piperazine for Melanoma Tumour Imaging; [18F]MEL054

P. Roselt, I. Greguric, T. Pham, 2013 .

First-in-human trial of 64 Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy

R. Hicks, M. Hofman, T. Akhurst, 2018 .

Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions

R. Hicks, M. Hofman, N. Aide, 2013, Nuclear medicine communications.

Radiosynthesis of a Novel PET Fluoronicotinamide for Melanoma Tumour PET Imaging; [18F]MEL050

O. Neels, P. Roselt, I. Greguric, 2011 .

Ex vivo and in vivo evaluation of (2R,3R)‐5‐[18F]‐fluoroethoxy‐ and fluoropropoxy‐benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter

M. Fulham, S. Eberl, R. Fulton, 2007, Synapse.

FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?

R. Tothill, L. Mileshkin, R. Hicks, 2020, The Journal of Nuclear Medicine.

Imaging immunity in patients with cancer using positron emission tomography

J. Trapani, D. de Ruysscher, G. Hanna, 2022, npj Precision Oncology.

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033

David Binns, Carleen Cullinane, D. Binns, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.

R. Fisher, R. Hicks, P. Roselt, 2019, Journal of Clinical Oncology.

Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging

B. Solomon, D. Binns, G. McArthur, 2005, Molecular Cancer Therapeutics.

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

G. Hanna, Daniel P Steinfort, M. MacManus, 2022, BMJ Open.

High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications

Thomas Beyer, Rodney J. Hicks, Jean-Mathieu Beauregard, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

18F-Flumazenil: A γ-Aminobutyric Acid A–Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy

Terence J O'Brien, David Binns, Marie-Claude Gregoire, 2013, The Journal of Nuclear Medicine.

FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?

R. Tothill, L. Mileshkin, R. Hicks, 2020, The Journal of Nuclear Medicine.